What's Happening?
Exactice Medical, Inc. has entered into a definitive agreement with ImSonic Medical, Inc. to develop the AIM device, a combined imaging and transseptal access solution. This device aims to make transseptal procedures faster, safer, and more cost-effective
by integrating 2D/3D intracardiac echocardiography (ICE) with a deployable steerable needle guide. The collaboration allows Exactice exclusive rights to develop, commercialize, and distribute ImSonic’s imaging technology within the AIM device, targeting electrophysiology and interventional cardiology procedures. The streamlined design of the AIM device simplifies transseptal access, improves precision targeting, and optimizes procedural workflow.
Why It's Important?
The development of the AIM device represents a significant advancement in cardiology, potentially transforming transseptal procedures, which are performed over a million times annually worldwide. By integrating imaging and access into a single device, the AIM device could enhance procedural precision, reduce risks, and improve efficiency, offering substantial benefits to clinicians, patients, and healthcare systems. This innovation aligns with the growing demand for safer and more efficient cardiac interventions, positioning Exactice and ImSonic as leaders in the medical imaging and interventional procedure market.
What's Next?
Following the completion of preclinical animal studies, Exactice plans to pursue 510(k) clearance for the AIM device, which would allow it to be marketed and used in clinical settings. The collaboration with ImSonic is expected to accelerate growth and innovation in the transseptal market, potentially leading to further advancements in cardiac procedures and expanded applications of the AIM device.
